NCT03450343View on ClinicalTrials.gov

Oral Azacitidine Plus Salvage Chemotherapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

April 4, 2019

Primary Completion Date

August 31, 2023

Study Completion Date

January 30, 2024

Conditions
Large B-Cell Diffuse Lymphoma
Interventions
DRUG

Oral azacitidine

Azacitidine can be taken with or without food at the same time every day.

DRUG

R-ICE

R-ICE is approved for the treatment of NHL before ASCT for relapsed or primary refractory diffuse large b-cell lymphoma. R-ICE consists of rituximab, etoposide, carboplatin and ifosfamide. R-ICE will be administered per institutional guidelines.

Trial Locations (1)

29425

Medical University of South Carolina, Charleston

Sponsors

Collaborators (1)

Celgene Corporation
All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

Medical University of South Carolina

OTHER